These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


684 related items for PubMed ID: 25854486

  • 21. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
    Weitz JI, Jaffer IH.
    Pol Arch Med Wewn; 2016 Sep 05; 126(9):688-696. PubMed ID: 27592622
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
    Dobesh PP, Fanikos J.
    Drugs; 2014 Nov 05; 74(17):2015-32. PubMed ID: 25300410
    [Abstract] [Full Text] [Related]

  • 25. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G, Becattini C, Franco L.
    Best Pract Res Clin Haematol; 2013 Jun 05; 26(2):151-61. PubMed ID: 23953903
    [Abstract] [Full Text] [Related]

  • 26. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
    Alcocer L.
    Am J Cardiovasc Drugs; 2016 Jun 05; 16(3):171-82. PubMed ID: 26923792
    [Abstract] [Full Text] [Related]

  • 27. Laboratory measurement of the direct oral anticoagulants.
    Dale BJ, Chan NC, Eikelboom JW.
    Br J Haematol; 2016 Feb 05; 172(3):315-36. PubMed ID: 26492202
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Jurisdictional Guidance on DOAC Use-Will It Affect Practice? A Comparison of European, American, and Canadian Product Monographs.
    Lamb DA, Bungard TJ, Lowerison J, Semchuk WM, Thomson P, Brocklebank C, Bolt J.
    Ann Pharmacother; 2020 Mar 05; 54(3):277-282. PubMed ID: 31529984
    [Abstract] [Full Text] [Related]

  • 30. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
    Proietti M, Lip GY.
    Expert Opin Pharmacother; 2015 Mar 05; 16(11):1573-6. PubMed ID: 26077323
    [Abstract] [Full Text] [Related]

  • 31. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J, Ageno W.
    Thromb Haemost; 2015 Feb 05; 113(2):231-46. PubMed ID: 25319150
    [Abstract] [Full Text] [Related]

  • 32. A Review on the New and Old Anticoagulants.
    Orthop Nurs; 2019 Feb 05; 38(1):53-54. PubMed ID: 30676578
    [No Abstract] [Full Text] [Related]

  • 33. [NOAC in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease].
    Gottsäter A.
    Lakartidningen; 2018 Dec 04; 115():. PubMed ID: 30512135
    [Abstract] [Full Text] [Related]

  • 34. [Novel oral anticoagulants--issues in clinical practice].
    Hohmann C, Neumann-Haefelin T, Radziwill R, Benöhr P.
    Med Monatsschr Pharm; 2015 Oct 04; 38(10):374-85; quiz 387-8. PubMed ID: 26731855
    [Abstract] [Full Text] [Related]

  • 35. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B, Faille D, Ajzenberg N.
    Med Sci (Paris); 2011 May 04; 27(5):493-500. PubMed ID: 21609670
    [Abstract] [Full Text] [Related]

  • 36. Insights From Practice With Use of Direct Oral Anticoagulants in Transplantation.
    Alsheikh R, Alfayez OM, Al Yami MS.
    Prog Transplant; 2018 Dec 04; 28(4):380-385. PubMed ID: 30222041
    [Abstract] [Full Text] [Related]

  • 37. Long-term benefits of preventing venous thromboembolic events.
    Cohen AT.
    Curr Med Res Opin; 2012 Jun 04; 28(6):877-89. PubMed ID: 22533680
    [Abstract] [Full Text] [Related]

  • 38. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment.
    McGrail R, Revsholm J, Nissen PH, Grove EL, Hvas AM.
    Thromb Res; 2016 Dec 04; 148():107-110. PubMed ID: 27835819
    [Abstract] [Full Text] [Related]

  • 39. Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
    Pan EY, Sobieraj DM.
    Conn Med; 2016 Feb 04; 80(2):105-11. PubMed ID: 27024982
    [No Abstract] [Full Text] [Related]

  • 40. New Oral Anticoagulants: What Prescribers Should Know; Differences and Similarities between Warfarin and "New Agents" (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) - Review of Indications, Contraindications and Safety of Use.
    Petrasko M, Raizada A, Petraskova T.
    S D Med; 2016 Aug 04; 69(8):363-369. PubMed ID: 28806005
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 35.